Elypta
Updated: March 01, 2026
Founders: Karl Bergman, Francesco Gatto
Country: Sweden | Funding: $33.6M (+)
Founded: 2017
Website: https://www.elypta.com/
Elypta is developing MIRAM - metabolomics-based liquid biopsy test for the early detection of cancer. MIRAM utilizes state-of-the-art laboratory methods for the extraction and detection of glycosaminoglycans (GAGs), delivering high and reliable performance in a standardized and scalable manner. The method is based on enzymatic digestion, which depolymerizes GAGs into disaccharides. Measurements can be performed in a wide range of research samples, such as blood, urine, tissue, cell cultures, and other biological fluids. Relatively small sample volumes are required to obtain accurate results across the entire glycosaminoglycan profile. The company is conducting a series of clinical studies to evaluate the effectiveness of its liquid biopsy in various cancer types.
Founded: 2017
Website: https://www.elypta.com/
Elypta is developing MIRAM - metabolomics-based liquid biopsy test for the early detection of cancer. MIRAM utilizes state-of-the-art laboratory methods for the extraction and detection of glycosaminoglycans (GAGs), delivering high and reliable performance in a standardized and scalable manner. The method is based on enzymatic digestion, which depolymerizes GAGs into disaccharides. Measurements can be performed in a wide range of research samples, such as blood, urine, tissue, cell cultures, and other biological fluids. Relatively small sample volumes are required to obtain accurate results across the entire glycosaminoglycan profile. The company is conducting a series of clinical studies to evaluate the effectiveness of its liquid biopsy in various cancer types.
